Guardant Health
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
Exact Sciences Blood-Based Colon Cancer Screening Data at ESMO Exceeds Expectations
Although the results were better than expected, the company cautioned that it expects lower performance in its prospective trial readout, planned for early next year.
Italian Hospital System to Offer Guardant360 CDx Liquid Biopsy Service for Cancer Therapy Selection
Rome-based Policlinico Gemelli will establish an in-house liquid biopsy testing service within its hospital system utilizing Guardant360 CDx.
Guardant Health Liquid Biopsy CDx Gets Japanese Regulatory Approval for Janssen Lung Cancer Drug
Patients with inoperable or recurrent NSCLC and EGFR exon 20 insertion mutations may be eligible for Janssen Pharmaceutical's amivantamab-vmjw.
Guardant Health Q2 Revenues Grow 29 Percent; Firm Raises Full-Year Guidance
Guardant reached a major milestone in Q2 with the FDA approval of its Guardant Shield liquid biopsy colon cancer screening test.